Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab + Pulsed Sonidegib in Advanced BCC
NCT04679480Phase 2Active, not recruiting
- Start
- Feb 2021
- Primary completion
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of cemiplimab in basal cell carcinoma (BCC). Started Feb 2021; status: active, not recruiting.
02
Drugs
cemiplimab
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT04679480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04679480.